Logo.png
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
March 28, 2024 09:00 ET | GRI Bio, Inc.
Live webcast on Wednesday, April 3rd at 10:10 AM ET LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an...
indaptus_logo.png
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
March 28, 2024 08:00 ET | Indaptus Therapeutics
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
22157.jpg
Cancer Immunotherapy Market Research 2024: The Race for the Cures - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer including Executive and Consultant Guides
March 13, 2024 11:26 ET | Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer...
inmunebio.jpg
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
March 05, 2024 08:00 ET | INmune Bio, Inc.
Patients with Alzheimer’s Disease show improvement in brainwaves following 4 weeks of XPro™ therapy. Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) --...
Remus_Vezan_800
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
February 27, 2024 10:30 ET | MAIA Biotechnology, Inc.
New Scientific Advisory Board member played instrumental role in FDA approval and commercialization of multiple blockbuster products CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA...
Logo.png
Follicular Lymphoma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies - AbbVie, Genmab, Novartis, Allogene Therapeutics, Pfizer, Genentech, Incyte Corporation, Bristol-Myers Squibb
February 26, 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Follicular Lymphoma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies - AbbVie, Genmab, Novartis, Allogene...
NurExone logo2.png
NurExone’s Intellectual Property Portfolio Expands
February 20, 2024 16:05 ET | NurExone Biologic Inc
NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production
Global Generic Oncology Drugs Market
Generic Oncology Drugs Global Research Report 2023: Market to Reach $33.18 Billion by 2027, Propelled by Rising Cancer Prevalence and Novel Formulations - Long-term Forecasts to 2032
February 08, 2024 09:38 ET | Research and Markets
Dublin, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The "Generic Oncology Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global market for generic oncology...
Global Vaccine Adjuvants Market
Vaccine Adjuvants Industry Forecast to 2034: A $7.36 Billion Market Opportunity, Dominated by Merck & Co, Thermo Fisher Scientific, and Pacific GeneTech
January 24, 2024 14:18 ET | Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Vaccine Adjuvants Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The global vaccine...
logo2 (1).png
IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine
January 24, 2024 03:00 ET | IMU Biosciences
Board strengthened with appointments of Tim Haines (Abingworth) as Non-executive Chair and Dr Oliver Nussbaumer (co-founder of GammaDelta Therapeutics and Adaptate Biotherapeutics) and Dr Inga Deakin...